Skip to main content

Advertisement

SpringerLink
Log in

Bone health in systemic lupus erythematosus

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Patients with systemic lupus erythematosus (SLE) confront an increased risk of developing osteoporosis and fragility fractures. Traditional risk factors, such as smoking, advanced age, physical inactivity, and low weight, are partly responsible, but a number of lupus-specific risk factors may also play an important role. Chronic, systemic inflammation in patients with SLE has been proposed as a possible mechanism for osteoporosis development. Other potential risk factors include vitamin D deficiency due to sun avoidance, premature gonadal failure, and the chronic use of medications known to increase osteoporosis risk. Increased awareness of this potentially preventable condition is warranted, as early detection and treatment help optimize bone health and improve long-term outcomes in patients with SLE. This article presents recent epidemiologic data related to bone health in SLE and discusses preventative and therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. World Health Organization: Prevention and management of osteoporosis: report of a WHO scientific group. In WHO Technical Report Series 921. Geneva, Switzerland: World Health Organization; 2000.

    Google Scholar 

  2. Lee C, Ramsey-Goldman R: Osteoporosis in systemic lupus erythematosus mechanisms. Rheum Dis Clin North Am 2005, 31:363–385.

    Article  PubMed  Google Scholar 

  3. Bultink IE, Lems WF, Kostense PJ, et al.: Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:2044–2050.

    Article  PubMed  Google Scholar 

  4. Formiga F, Nolla JM, Moga I, Roig-Escofet D: Sequential study of bone mineral density in patients with systemic lupus erythematosus. Ann Rheum Dis 1996, 55:857.

    Article  PubMed  CAS  Google Scholar 

  5. Boyanov M, Robeva R, Popivanov P: Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 2003, 22:318–323.

    Article  PubMed  CAS  Google Scholar 

  6. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L: Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993, 36:1726–1734.

    Article  PubMed  CAS  Google Scholar 

  7. Formiga F, Moga I, Nolla JM, et al.: Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995, 54:274–276.

    Article  PubMed  CAS  Google Scholar 

  8. Petri M: Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995, 8:137–145.

    Article  PubMed  CAS  Google Scholar 

  9. Kipen Y, Buchbinder R, Forbes A, et al.: Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 1997, 24:1922–1929.

    PubMed  CAS  Google Scholar 

  10. Sinigaglia L, Varenna M, Binelli L, et al.: Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 1999, 26:1280–1284.

    PubMed  CAS  Google Scholar 

  11. Gilboe IM, Kvien TK, Haugeberg G, Husby G: Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis 2000, 59:110–115.

    Article  PubMed  CAS  Google Scholar 

  12. Bhattoa HP, Bettembuk P, Balogh A, et al.: Bone mineral density in women with systemic lupus erythematosus. Clin Rheumatol 2002, 21:135–141.

    Article  PubMed  CAS  Google Scholar 

  13. Almehed K, Forsblad d’Elia H, Kvist G, et al.: Prevalence and risk factors of osteoporosis in female SLE patients—extended report. Rheumatology (Oxford) 2007, 46:1185–1190.

    Article  CAS  Google Scholar 

  14. Lee C, Almagor O, Dunlop DD, et al.: Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 2006, 45:53–60.

    Article  CAS  Google Scholar 

  15. Mok CC, Mak A, Ma KM: Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 2005, 14:106–112.

    Article  PubMed  CAS  Google Scholar 

  16. Teichmann J, Lange U, Stracke H, et al.: Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 1999, 18:137–140.

    Article  PubMed  CAS  Google Scholar 

  17. Kalla AA, van Wyk Kotze TJ, Meyers OL: Metacarpal bone mass in systemic lupus erythematosus. Clin Rheumatol 1992, 11:475–482.

    Article  PubMed  CAS  Google Scholar 

  18. Angeli A, Guglielmi G, Dovio A, et al.: High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006, 39:253–259.

    Article  PubMed  CAS  Google Scholar 

  19. Uaratanawong S, Deesomchok U, Hiransuttikul N, Uaratanawong S: Four years follow-up of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Med Assoc Thai 2004, 87:1374–1379.

    PubMed  Google Scholar 

  20. Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S: Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 2003, 30:2365–2368.

    PubMed  Google Scholar 

  21. Korczowska I, Olewicz-Gawlik A, Hrycaj P, Lacki J: The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorption. Yale J Biol Med 2003, 76:45–54.

    PubMed  CAS  Google Scholar 

  22. Yee CS, Crabtree N, Skan J, et al.: Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:111–113.

    Article  PubMed  Google Scholar 

  23. de Deus RB, Ferreira AC, Kirsztajn GM, Heilberg IP: Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy. Nephron Clin Pract 2003, 94:c69–c74.

    Article  PubMed  Google Scholar 

  24. Coimbra IB, Costallat LT: Bone mineral density in systemic lupus erythematosus and its relation to age at disease onset, plasmatic estradiol and immunosuppressive therapy. Joint Bone Spine 2003, 70:40–45.

    Article  PubMed  Google Scholar 

  25. Becker A, Fischer R, Scherbaum WA, Schneider M: Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 2001, 10:809–814.

    Article  PubMed  CAS  Google Scholar 

  26. Bhattoa HP, Kiss E, Bettembuk P, Balogh A: Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int 2001, 21:97–102.

    Article  PubMed  CAS  Google Scholar 

  27. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N: Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001, 28:102–108.

    PubMed  CAS  Google Scholar 

  28. Jardinet D, Lefèbvre C, Depresseux G, et al.: Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 2000, 39:389–392.

    Article  CAS  Google Scholar 

  29. Li EK, Tam LS, Young RP, et al.: Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. Br J Rheumatol 1998, 37:405–410.

    Article  PubMed  CAS  Google Scholar 

  30. Formiga F, Nolla JM, Mitjavila F, et al.: Bone mineral density and hormonal status in men with systemic lupus erythematosus. Lupus 1996, 5:623–626.

    Article  PubMed  CAS  Google Scholar 

  31. Houssiau FA, Lefèbvre C, Depresseux G, et al.: Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996, 35:244–247.

    Article  PubMed  CAS  Google Scholar 

  32. Dhillon VB, Davies MC, Hall ML, et al.: Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry. Ann Rheum Dis 1990, 49:624–626.

    Article  PubMed  CAS  Google Scholar 

  33. Redlich K, Ziegler S, Kiener HP, et al.: Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 2000, 59:308–310.

    Article  PubMed  CAS  Google Scholar 

  34. Hansen M, Halberg P, Kollerup G, et al.: Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scand J Rheumatol 1998, 27:197–206.

    Article  PubMed  CAS  Google Scholar 

  35. Mok CC, Ying SK, To CH, Ma KM: Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone 2008, 43:327–331.

    Article  PubMed  Google Scholar 

  36. Lilleby V: Bone status in juvenile systemic lupus erythematosus. Lupus 2007, 16:580–586.

    Article  PubMed  CAS  Google Scholar 

  37. Lilleby V, Lien G, Frey Froslie K, et al.: Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum 2005, 52:2051–2059.

    Article  PubMed  Google Scholar 

  38. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu K, et al.: Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007, 56:1966–1973.

    Article  PubMed  Google Scholar 

  39. Ramsey-Goldman R, Dunn JE, Huang CF, et al.: Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999, 42:882–890.

    Article  PubMed  CAS  Google Scholar 

  40. Lee C, Almagor O, Dunlop DD, et al.: Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 2007, 34:2018–2023.

    PubMed  Google Scholar 

  41. Borba VZ, Matos PG, da Silva Viana PR, et al.: High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 2005, 14:529–533.

    Article  PubMed  CAS  Google Scholar 

  42. McLean RR, Jacques PF, Selhub J, et al.: Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004, 350:2042–2049.

    Article  PubMed  CAS  Google Scholar 

  43. Rhew EY, Lee C, Eksarko P, et al.: Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. J Rheumatol 2008, 35:230–236.

    PubMed  Google Scholar 

  44. Pons F, Peris P, Guañabens N, et al.: The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol 1995, 34:742–746.

    Article  PubMed  CAS  Google Scholar 

  45. Neff MJ: ACOG releases guidelines for clinical management of osteoporosis. Am Fam Physician 2004, 69:1558,1560.

    PubMed  Google Scholar 

  46. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44:1496–1503.

  47. Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167(10 Suppl):S1–34.

    PubMed  Google Scholar 

  48. Lambrinoudaki I, Chan DT, Lau CS, et al.: Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 2000, 27:1759–1765.

    PubMed  CAS  Google Scholar 

  49. Kung AW, Chan TM, Lau CS, et al.: Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 1999, 38:1239–1244.

    Article  CAS  Google Scholar 

  50. Lakatos P, Nagy Z, Kiss L, et al.: Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000, 59(Suppl 1):48–52.

    Article  PubMed  Google Scholar 

  51. Chong HC, Chee SS, Goh EM, et al.: Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus. Clin Rheumatol 2007, 26:182–185.

    Article  PubMed  CAS  Google Scholar 

  52. Bhattoa HP, Bettembuk P, Balogh A, et al.: The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2004, 15:396–404.

    Article  PubMed  CAS  Google Scholar 

  53. Manson JE, Hsia J, Johnson KC, et al.: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523–534.

    Article  PubMed  CAS  Google Scholar 

  54. Mok CC, To CH, Mak A, Ma KM: Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 2005, 52:3997–4002.

    Article  PubMed  CAS  Google Scholar 

  55. Abdou NI, Rider V, Greenwell C, et al.: Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 2008, 35:797.

    PubMed  CAS  Google Scholar 

  56. Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, et al.: Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 2008, 35:1567–1575.

    PubMed  CAS  Google Scholar 

  57. Cranney A, Welch V, Adachi JD, et al.: Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000, 2:CD001983.

    PubMed  Google Scholar 

  58. Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437–1443.

    Article  PubMed  CAS  Google Scholar 

  59. Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535–1541.

    Article  PubMed  CAS  Google Scholar 

  60. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344–1352.

    Article  PubMed  CAS  Google Scholar 

  61. McClung MR, Geusens P, Miller PD, et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333–340.

    Article  PubMed  CAS  Google Scholar 

  62. Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382–387.

    Article  PubMed  CAS  Google Scholar 

  63. Roux C, Oriente P, Laan R, et al.: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998, 83:1128–1133.

    Article  PubMed  CAS  Google Scholar 

  64. Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292–299.

    Article  PubMed  CAS  Google Scholar 

  65. Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202–211.

    Article  PubMed  CAS  Google Scholar 

  66. Shane E, Addesso V, Namerow PB, et al.: Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004, 350:767–776.

    Article  PubMed  CAS  Google Scholar 

  67. Eastell R, Devogelaer JP, Peel NF, et al.: Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000, 11:331–337.

    Article  PubMed  CAS  Google Scholar 

  68. Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309–2318.

    Article  PubMed  CAS  Google Scholar 

  69. Reid DM, Hughes RA, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000, 15:1006–1013.

    Article  PubMed  CAS  Google Scholar 

  70. Nzeusseu Toukap A, Depresseux G, Devogelaer JP, Houssiau FA: Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 2005, 14:517–520.

    Article  PubMed  CAS  Google Scholar 

  71. Buyon JP, Petri MA, Kim MY, et al.: The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005, 142(12 Pt 1):953–962.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Rheumatology, McGill University Health Center, Montreal General Hospital, 1650 Cedar Avenue, Room A6-123, Montreal, Quebec, H3G 1A4, Canada

    Pantelis Panopalis

Authors
  1. Pantelis Panopalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinoos Yazdany
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pantelis Panopalis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Panopalis, P., Yazdany, J. Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 11, 177–184 (2009). https://doi.org/10.1007/s11926-009-0024-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0024-2

Keywords

Search

Navigation